Medicines and diagnostics in Mozambique and Fiji
Evaluating adoption, availability, price and affordability of essential CVD medicines and diagnostics in Mozambique and Fiji
Low and low-middle income countries are facing a growing burden of deaths due to cerebrovascular and ischemic heart diseases which are largely avoidable with good access to essential medicines and diagnostics. To meet World Heart Federation’s 25x25 target of reducing cardiovascular disease (CVD) deaths by 25% by year 2025, countries must achieve 80% availability of essential medicines (EMs) and technologies in all facilities. However, there are no baseline data on in-country access to CVD treatments in many countries, including Mozambique and Figi.
Study objectives: This study therefore aims to conduct a cross-sectional survey based on World Health Organization (WHO)/Health Action International methodology to collect data on availability and price of 14 WHO Core EMs, 31 additional CVD EMs and 19 routine CVD diagnostic tests in a representative sample of major public-sector and private-sector hospitals along with private retail pharmacies. Specifically, the study aims to:
Review medicine lists, government documents and local treatment guidelines in Mozambique and Fiji to describe adoption of the WHO Model EML
Compile a comprehensive list of medicines and diagnostic tools for CVD in adults (including pregnant women) and children
Assess the availability, prices and affordability of essential CVD medicines and diagnostics in the public and private sector in Mozambique and Fiji